• Ascendis Pharma A/S ASND.OQ, ASND.O is expected to show a rise in quarterly revenue when it reports results on November 14 for the period ending January 1 0001

• The Hellerup Denmark-based company is expected to report a 71.5% increase in revenue to $82.364 million from $48.03 million a year ago, according to the mean estimate from 11 analysts, based on LSEG data.

• ​LSEG's mean analyst estimate for Ascendis Pharma A/S is for a loss of $1.74 per share.

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts had fallen by about 0.9% in the last three months. ​

• Wall Street's median 12-month price target for Ascendis Pharma A/S is 191.00​, above​ its last closing price of $127.67. ​​​

Previous quarterly performance (using preferred earnings measure in euros). ​

This summary was machine generated November 13 at 00:04 GMT. All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)